Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Lamivudine/raltegravir
Другие языки:

Lamivudine/raltegravir

Подписчиков: 0, рейтинг: 0

Lamivudine/raltegravir
Combination of
Lamivudine Reverse-transcriptase inhibitor
Raltegravir Integrase inhibitor
Clinical data
Trade names Dutrebis
Routes of
administration
Oral
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS. It contains lamivudine and raltegravir. It is taken by mouth. Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes. It was approved for medical use in the United States in 2015.

Lamivudine/raltegravir is not available in the United States.

External links



Новое сообщение